about
Semaphorin 3F forms an anti-angiogenic barrier in outer retina.Switch of anti-VEGF agents is an option for nonresponders in the treatment of AMD[Intravitreal drug therapy for retinal vein occlusion--pathophysiological mechanisms and routinely used drugs].Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusionCathepsin proteases promote angiogenic sprouting and laser-induced choroidal neovascularisation in mice.Efficacy and safety of intravitreal therapy in macular edema due to branch and central retinal vein occlusion: a systematic review.Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES): six-month results of a prospective randomized clinical trial.Increased expression of angiogenic and inflammatory proteins in the vitreous of patients with ischemic central retinal vein occlusion.[Retinal vein occlusion: Therapy of retinal vein occlusion].Predictors of prognosis and treatment outcome in central retinal artery occlusion: local intra-arterial fibrinolysis vs. conservative treatment.miR-145 Is a Promising Therapeutic Target to Prevent Cornea Scarring.Switch of Intravitreal Therapy for Macular Edema Secondary to Retinal Vein Occlusion from Anti-VEGF to Dexamethasone Implant and Vice Versa.Cardiovascular Risk Factors in Central Retinal Artery Occlusion: Results of a Prospective and Standardized Medical Examination.[Retinal vein occlusion : Epidemiology, classification and clinical findings].Histone deacetylase inhibitors sodium butyrate and valproic acid delay spontaneous cell death in purified rat retinal ganglion cells.[Clinical diagnostics and therapy for non-arteritic central retinal artery occlusion].[Perioperative conversion of oral anticoagulants to heparin (bridging) in ophthalmic medicine].Retinal ganglion cell survival is enhanced by gabapentin-lactam in vitro: evidence for involvement of mitochondrial KATP channels.The peptides ADNF-9 and NAP increase survival and neurite outgrowth of rat retinal ganglion cells in vitro.Visual and anatomic outcomes after conversion to aflibercept in neovascular age-related macular degeneration: 12-month results.Bilateral serous retinal detachment.Injection scheme for intravitreal bevacizumab therapy for macular oedema due to central retinal vein occlusion: results of a multicentre study.Injection scheme for intravitreal bevacizumab therapy for macular oedema due to central retinal vein occlusion: results of a multicenter study.Correlation Between Hyperreflective Foci and Clinical Outcomes in Neovascular Age-Related Macular Degeneration After Switching to Aflibercept.Intravitreal Ranibizumab versus Isovolemic Hemodilution in the Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion: Twelve-Month Results of a Prospective, Randomized, Multicenter TrialEmpfehlungen der DOG zu Publikationsregelungen in MultizenterstudienMitteilungen der DOGIntra- and Postoperative Risks and Complications of Small-Gauge (23-G) versus Conventional (20-G) Vitrectomy for Macular SurgeryLevels of VEGF but not VEGF 165b are Increased in the Vitreous of Patients With Retinal Vein OcclusionOkuläres IschämiesyndromOptical coherence tomography angiography analysis of macular flow density in glaucoma.Ranibizumab Pro Re nata versus Dexamethasone in the Management of Ischemic Retinal Vein Occlusion: Post-hoc Analysis from the COMRADE TrialsComparison of Macular Pigment Optical Density in Glaucoma Patients and Healthy Subjects - A Prospective Diagnostic Study
P50
Q33593419-5AF6532D-B0E0-4202-8958-B930E431F016Q33595182-9F46791C-BE6F-49BF-9F5B-A95A2B46E62EQ33693620-447F3420-FAC2-40E3-8317-636404925459Q34588134-25BBAF69-C5A5-47A1-A597-41F337DD2079Q34783913-65C6F166-B529-43D7-B074-82C57A358AA7Q35036495-7E7D29FE-2496-466E-B690-FEE92A6FCC50Q35209724-05A48066-7C32-48C7-BB8A-88BEBB40AB94Q35610722-73C8838C-C743-4413-8313-516B6FB1A21CQ35737854-0F77901A-E9F1-4BBB-8EAD-7A1AEE007B28Q40562643-477D139D-6AF1-40C0-8C7B-DCF8D5CFE735Q41112641-2F8D9981-8E6A-40B3-931F-26C56E762ECFQ41371210-7D895DC3-E4AB-40F2-B2F7-5DDAE90099EFQ41525632-4DE32DCB-C829-4F42-BE7E-2F55D577F8FAQ41596356-73493F00-0E41-4226-BDA1-F5336AC1216EQ41887005-F6956BE0-2959-4D26-BCC3-12EDC3FA695BQ42906094-0F8805F8-8523-4F10-8342-DF7831F933BEQ43213535-94802E5E-51ED-41C2-9196-8819416C3435Q44760742-A7F500A5-F65F-4547-80E9-C8C737667EDBQ45280872-4A94831C-96CC-4E6F-BA47-6FA2A826AE53Q48913302-77D922C6-2BEE-43A3-9C3B-D46E32E938F9Q51046482-B919DA66-9CFA-4364-A9F2-5CCB7BFA6C1DQ52857001-C31AE744-D6B2-4DBD-9308-2E4A010EA99CQ52870293-1638A58D-5AA3-4FBD-90EA-6AEA594C8FEFQ53319301-75F4022D-2112-40FE-897D-176361ADD840Q59938626-6B8E49B8-A385-4DAA-8932-23836E92530EQ59938655-4F41DFA7-898D-4F77-B269-C1D3031612ABQ59938682-AE95A2EC-4125-4228-ABC9-C56836AA4C00Q59938695-B91AFFEC-7C65-429F-95C3-BD07F94A9481Q59938737-81E6C18B-C1B3-470C-B8A0-A3B00AF0C034Q59938741-3C30F79D-3503-4E2F-B8EB-D41349388D76Q64934637-A987A8FE-FDC9-4FA4-BA50-53DC291D727EQ91008964-D945145A-A86F-4BD7-9192-86035176799FQ92059612-FA011936-1EFB-4381-A752-360FE3C36FCA
P50
description
hulumtuese
@sq
oogarts
@nl
researcher
@en
ricercatrice
@it
հետազոտող
@hy
name
Amelie Pielen
@ast
Amelie Pielen
@en
Amelie Pielen
@es
Amelie Pielen
@nl
Amelie Pielen
@sl
type
label
Amelie Pielen
@ast
Amelie Pielen
@en
Amelie Pielen
@es
Amelie Pielen
@nl
Amelie Pielen
@sl
prefLabel
Amelie Pielen
@ast
Amelie Pielen
@en
Amelie Pielen
@es
Amelie Pielen
@nl
Amelie Pielen
@sl
P214
P227
P21
P213
0000 0000 2076 9969
P214
P227
P31
P496
0000-0001-9401-2501
P569
1978-01-01T00:00:00Z
P735
P7859
viaf-25708699